Contributions
Abstract: P706
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Clinical assessment tools
Background: There is increasing interest in the role of the cerebellum in multiple sclerosis (MS).
Objectives: To investigate the longitudinal relation of cognition to cerebellar function in relapsing-remitting MS (RR-MS) and how these relate to motor function and planning.
Aim: To develop a clinical measure of cerebellar function.
Methods: 11 RRMS patients with cerebellar symptomatology (RR-MSc: EDSS x̅: 4.55, 5 males, x̅ age: 41), 17 RRMS patients without cerebellar symptomatology (RR-MSnc: EDSS x̅: 3.03, 2 males, x̅ age: 40.94) and 9 matched control participants (C: 2 males, x̅ age: 37.78) completed the Brief International Cognitive Assessment for MS (BICAMS: Brief Visual Memory Test -Revised, BVMT-R; California Verbal Learning Test-II, CVLT-II; Symbol Digit Modalities Test, SDMT), the Nine-Hole Peg test (NHPT) and the Grooved Pegboard Test (GPT) at baseline and 12 months. The NHPT measures manual dexterity and the GPT has greater motor planning demands. The GPT - NHPT difference was used to compute a motor planning index (MPI), the NHPT serving as a control for sensorimotor impairment.
Results: The means and standard deviations for the C, RRMSnc and RRMSc were respectively: CVLT-II: 55.22 (10.34), 52.18 (11.27), 38.82 (9.01); SDMT: 56.67 (8.92), 52.06 (11.86), 39.73 (10.57); BVMT-R: 24.89 (5.53), 24.65 (8.15), 19.00 (9.77); NHPT: 18.32 (1.29), 21.22 (2.26), 28.61 (5.51); GPT: 51.78 (2.54), 65.62 (16.33), 96.97 (37.12); MPI: 33.35 (2.21), 43.81 (13.87), 68.35 (33.42). A 2 x 3 mixed ANOVA revealed a consistent significant group separation on the CVLT-II (F(2,34) = 8.52, p = .001), SDMT (F(2,34) = 6.12, p = .005), NHPT (F(2,34) = 29.11, p < .001), GPT (F(2,34) = 11.74, p < .001) and MPI (F(2,34) = 14.19, p < .001) but not for the BVMT-R (F(2,34) = .387, p = .682). There was a significant effect of time for the BVMT-R (F(1,34) = 4.74, p = .037) and the CVLT-II (F(1,34) = 18.83, p < .001). There was a significant correlation between the SDMT and MPI (r(27)= -.611, p< .001).
Conclusions: RRMSc were characterised by greater impairment on tests of cognition, motor function and motor planning than the RRMSnc. These differences were maintained over a year. The association of the MPI and SDMT indicates information processing speed may act as a mediator of motor planning. The next step is to validate the MPI with an MRI study exploring how it relates to cerebellar lesion load and atrophy.
Disclosure: JC: Nothing to disclose.
KA-A: Consultancy from Merck; sponsored educational activities from TEVA, Biogen, Novartis, Merck and Sanofi Genzyme.
DL: Consultancy from Novartis, Bayer, TEVA, Biogen, Merck; Speaker bureau for Almirall, TEVA, Biogen, Novartis, Bayer, Excemed; Research grants from Novartis, Biogen, Bayer, Merck. All are paid into DL's university.
Abstract: P706
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Clinical assessment tools
Background: There is increasing interest in the role of the cerebellum in multiple sclerosis (MS).
Objectives: To investigate the longitudinal relation of cognition to cerebellar function in relapsing-remitting MS (RR-MS) and how these relate to motor function and planning.
Aim: To develop a clinical measure of cerebellar function.
Methods: 11 RRMS patients with cerebellar symptomatology (RR-MSc: EDSS x̅: 4.55, 5 males, x̅ age: 41), 17 RRMS patients without cerebellar symptomatology (RR-MSnc: EDSS x̅: 3.03, 2 males, x̅ age: 40.94) and 9 matched control participants (C: 2 males, x̅ age: 37.78) completed the Brief International Cognitive Assessment for MS (BICAMS: Brief Visual Memory Test -Revised, BVMT-R; California Verbal Learning Test-II, CVLT-II; Symbol Digit Modalities Test, SDMT), the Nine-Hole Peg test (NHPT) and the Grooved Pegboard Test (GPT) at baseline and 12 months. The NHPT measures manual dexterity and the GPT has greater motor planning demands. The GPT - NHPT difference was used to compute a motor planning index (MPI), the NHPT serving as a control for sensorimotor impairment.
Results: The means and standard deviations for the C, RRMSnc and RRMSc were respectively: CVLT-II: 55.22 (10.34), 52.18 (11.27), 38.82 (9.01); SDMT: 56.67 (8.92), 52.06 (11.86), 39.73 (10.57); BVMT-R: 24.89 (5.53), 24.65 (8.15), 19.00 (9.77); NHPT: 18.32 (1.29), 21.22 (2.26), 28.61 (5.51); GPT: 51.78 (2.54), 65.62 (16.33), 96.97 (37.12); MPI: 33.35 (2.21), 43.81 (13.87), 68.35 (33.42). A 2 x 3 mixed ANOVA revealed a consistent significant group separation on the CVLT-II (F(2,34) = 8.52, p = .001), SDMT (F(2,34) = 6.12, p = .005), NHPT (F(2,34) = 29.11, p < .001), GPT (F(2,34) = 11.74, p < .001) and MPI (F(2,34) = 14.19, p < .001) but not for the BVMT-R (F(2,34) = .387, p = .682). There was a significant effect of time for the BVMT-R (F(1,34) = 4.74, p = .037) and the CVLT-II (F(1,34) = 18.83, p < .001). There was a significant correlation between the SDMT and MPI (r(27)= -.611, p< .001).
Conclusions: RRMSc were characterised by greater impairment on tests of cognition, motor function and motor planning than the RRMSnc. These differences were maintained over a year. The association of the MPI and SDMT indicates information processing speed may act as a mediator of motor planning. The next step is to validate the MPI with an MRI study exploring how it relates to cerebellar lesion load and atrophy.
Disclosure: JC: Nothing to disclose.
KA-A: Consultancy from Merck; sponsored educational activities from TEVA, Biogen, Novartis, Merck and Sanofi Genzyme.
DL: Consultancy from Novartis, Bayer, TEVA, Biogen, Merck; Speaker bureau for Almirall, TEVA, Biogen, Novartis, Bayer, Excemed; Research grants from Novartis, Biogen, Bayer, Merck. All are paid into DL's university.